Endothelium-derived relaxing factor

Department of Cardiology, University of Wales College of Medicine, Heath Park, Cardiff, United Kingdom.

This article reviews what is known of endothelium-derived relaxing factor and its possible physiologic and pathophysiologic roles. This relaxing factor is now thought to be nitric oxide or a ready source of it. It acts as an endogenous nitrovasodilator, stimulating soluble guanylate cyclase to increase cyclic guanosine monophosphate (GMP) levels in vascular smooth muscle and platelets, with consequent relaxant and anti-aggregatory effects (predominantly when stimulated through receptor-operated channels). Its actions are thus synergistic with those of cyclic adenosine monophosphate (AMP)-mediated stimulation (for example, adenosine, prostacyclin). Endothelium-derived relaxing factor is unstable and is thought to act only very locally in vivo. Its release is continuous in the basal state and is stimulated by a number of neuropeptides and by agents released during platelet activation and thrombosis--with large differences in activity among different vessels. Endothelium-derived relaxing factor activity is also flow related, thereby coordinating vasomotor behavior in an intact vascular tree in response to changes in flow. Endothelium-derived relaxing factor activity is reduced in several pathologic states, including atherosclerosis.

This article has been cited by other articles:

				K.W. Park, H.B. Dai, E. Lowenstein, A. Darvish, and F.W. Sellke Isoflurane Attenuates cAMP-Mediated Vasodilation in Rat Microvessels Circulation, November 1, 1995; 92(9): 423 - 427. [Abstract] [Full Text]

				V. Schachinger and A. M. Zeiher Quantitative Assessment of Coronary Vasoreactivity in Humans In Vivo : Importance of Baseline Vasomotor Tone in Atherosclerosis Circulation, October 15, 1995; 92(8): 2087 - 2094. [Abstract] [Full Text]

				A. M. Zeiher, V. Schachinger, and J. Minners Long-term Cigarette Smoking Impairs Endothelium-Dependent Coronary Arterial Vasodilator Function Circulation, September 1, 1995; 92(5): 1094 - 1100. [Abstract] [Full Text]

				A. Giaid and D. Saleh Reduced Expression of Endothelial Nitric Oxide Synthase in the Lungs of Patients with Pulmonary Hypertension N. Engl. J. Med., July 27, 1995; 333(4): 214 - 221. [Abstract] [Full Text] [PDF]

				F. Mohamed, J. C. Monge, A. Gordon, P. Cernacek, D. Blais, and D. J. Stewart Lack of Role for Nitric Oxide (NO) in the Selective Destabilization of Endothelial NO Synthase mRNA by Tumor Necrosis Factor–{alpha} Arterioscler. Thromb. Vasc. Biol., January 1, 1995; 15(1): 52 - 57. [Abstract] [Full Text]

				A. Giaid, M. Yanagisawa, D. Langleben, R. P. Michel, R. Levy, H. Shennib, S. Kimura, T. Masaki, W. P. Duguid, and D. J. Stewart Expression of Endothelin-1 in the Lungs of Patients with Pulmonary Hypertension N. Engl. J. Med., June 17, 1993; 328(24): 1732 - 1739. [Abstract] [Full Text]

				R.H. Morgan, G. Carolan, J.V. Psaila, A.M.N. Gardner, R.H. Fox, and J.P. Woodcock Arterial Flow Enhancement by Impulse Compression Vascular and Endovascular Surgery, January 1, 1991; 25(1): 8 - 16. [Abstract] [PDF]